InsidersTradesSigma
Follow the Swedish Orphan Biovitrum AB (Sobi) share price and the full management transaction log of the company, a publicly traded company based in Finland. Shares are quoted on FI FI, under the authority of FIN-FSA. Market capitalisation: €154.7bn. The latest transaction was filed on 5 March 2021 (Purchase). Among the most active insiders: Helena Saxon. All data is accessible without an account.
Analysts rate Swedish Orphan Biovitrum AB (Sobi) Buy (bullish), based on 12 analysts. Average price target: SEK 471.67.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
1 of 1 declaration
Swedish Orphan Biovitrum AB (Sobi) is a Swedish biopharmaceutical company focused on developing treatments for rare diseases. It specializes in products for hematological disorders and genetic diseases.